MMTX MMTX
Company Profile ↓Company Overview
MMTX (MMTX) is a publicly traded company listed on with a market capitalization of $89.16M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +2.12% |
| 6 Months: | +1.00% |
| 3 Months: | +0.40% |
| 1 Month: | -0.20% |
- Price vs 50-DMABelow
- RSI (14)46.02 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 44.13K | 110.85K | 149.75K |
| Operating Income | -44.13K | -110.85K | -149.75K |
| EBITDA | -44.13K | -110.85K | -149.75K |
| Interest Expense | - | - | - |
| Pretax Income | -44.13K | 360.64K | 462.46K |
| Tax Provision | - | - | - |
| Net Income | -44.13K | 360.64K | 462.46K |
| Diluted EPS | -0.01 | - | 0.05 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Total Assets | 70.22M |
| Current Assets | 752.01K |
| Cash & Equivalents | 692.00K |
| Inventory | - |
| Receivables | - |
| Total Liabilities | 740.75K |
| Current Liabilities | 50.75K |
| Long Term Debt | - |
| Total Debt | - |
| Total Equity | 69.48M |
| Shares Outstanding | 8.83M |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MMTX
MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy
MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable, precision neurotherapeutics, today announced that its technology is being used in a University of Pittsburgh study evaluating …
MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe
MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced that the SwissNeuroRehab consortium has enrolled the first patients in a High-Dose…
MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting
MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today published the invitation to its 2026 Annual General Meeting (AGM), which will be held on Jun…
CADV Ventures S.A. to Combine with Miluna Acquisition Corp to Become a Publicly Listed Company
Warsaw, Poland and Taipei, Taiwan, April 27, 2026 (GLOBE NEWSWIRE) -- CADV Ventures S.A., an AI software company founded in 2017 and headquartered in Warsaw, Poland, focused on improving digital customer engagement for large organizations (…
MindMaze Therapeutics Publishes 2025 Annual Report and Corporate Update
Positive real-world evidence results from multi-site program conducted with Vibra Healthcare Established clinical and commercial foundation in neurological care Advancement of U.S. commercial expansion and reimbursement strategy Appointment…
Edison Issues Report on MindMaze Therapeutics (MMTX)
London, United Kingdom--(Newsfile Corp. - April 7, 2026) - Edison issues report on MindMaze Therapeutics (SIX: MMTX).MindMaze Therapeutics is a commercial-stage health technology company pioneering AI-driven digital neurotherapeutic solutio…
MMTX — Frequently Asked Questions
What is the current share price of MMTX?
As of 2026-08-05 17:25 PDT, MMTX trades at $10.10 on NASDAQ/NYSE. Its 52-week range is $9.88 to $10.15.
What is the market capitalisation of MMTX?
MMTX has a market capitalisation of $89.16M on NASDAQ/NYSE.
Is MMTX a good stock to buy?
This page provides a data-driven analysis of MMTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.